Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Oct 15, 2019; 11(10): 866-876
Published online Oct 15, 2019. doi: 10.4251/wjgo.v11.i10.866
Published online Oct 15, 2019. doi: 10.4251/wjgo.v11.i10.866
Table 3 Baseline characteristics of the study population
| Baseline characteristics | LMWH (%) | DOACs (%) | Apixaban (%) | Rivaroxaban (%) |
| N (%) | 40 | 66 | 29 (44) | 37 (56) |
| Age at cancer diagnosis (median years) | 66 | 67 | 68 | 65 |
| (range) | 37-80 | 37-83 | 43-83 | 37-79 |
| Age at VTE event (median years) | 66 | 68 | 68 | 65 |
| (range) | 40-80 | 37-83 | 43-83 | 37-79 |
| Weight (median kg) | 71.0 | 73.0 | 69.5 | 77.0 |
| (range) | 42-130 | 42-168 | 42-168 | 56-130 |
| Gender (Male) | 18 (45) | 41 (62) | 17 (59) | 24 (65) |
| Race (white) | 32 (80) | 52 (79) | 21 (72) | 31 (84) |
| Current smoker | 10 (25) | 12 (18) | 6 (21) | 6 (15) |
| Antiplatelet therapy | 5 (12.5) | 8 (12) | 5 (17) | 3 (8) |
| Prior treated VTE | 2 (5) | 7 (11) | 2 (7) | 5 (13) |
| Cancer diagnosis | ||||
| Pancreas | 15 (37.5) | 28 (42) | 14 (50) | 14 (38) |
| Colon | 8 (20) | 18 (27) | 8 (25) | 10 (27) |
| Rectal | 2 (5) | 5 (8) | 1 (3.5) | 4 (11) |
| NET | 3 (7.5) | 4 (6) | 1 (3.5) | 3 (8) |
| Gastric | 4 (10) | 3 (5) | 1 (3.5) | 2 (5) |
| Esophageal | 0 | 3 (5) | 1 (3.5) | 2 (5) |
| Appendix | 1 (2.5) | 3 (5) | 2 (7) | 1 (3) |
| Biliary | 3 (7.5) | 1 (1) | 1 (3.5) | 0 |
| GEJ | 1 (2.5) | 1 (1) | 0 | 1 (3) |
| HCC | 3 (7.5) | 0 | 0 | 0 |
| Stage at VTE diagnosis | ||||
| I | 1 (2.5) | 1 (1) | 1 (3.5) | 0 |
| II | 7 (17.5) | 7 (11) | 3 (10.75) | 4 (10) |
| III | 3 (7.5) | 12 (19) | 3 (10.75) | 9 (25) |
| IV | 29 (72.5) | 46 (69) | 22 (75) | 24 (65) |
| Prior chemotherapy | 24 (40) | 24 (36) | 11 (38) | 13 (35) |
| Current chemotherapy | 24 (40) | 29 (47) | 18 (62) | 13 (35) |
| VTE diagnosis | ||||
| PE/DVT | 11 (27.5) | 8 (12) | 5 (17) | 3 (8) |
| PE | 7 (17.5) | 8 (12) | 2 (7) | 6 (16) |
| DVT | 22 (55) | 50 (75) | 22 (75) | 28 (76) |
| Identifiable risk factor | 10 (16) | 5 (17) | 5 (14) | |
| Recent surgery/Hospitalization | 2 (5) | 4 (6) | 3 (10) | 1 (3) |
| Central venous catheter | 2 (5) | 6 (9) | 2 (7) | 4 (11) |
| Khorana score | ||||
| Low | 11 (27.5) | 19 (28) | 7 (24) | 12 (32) |
| Intermediate | 18 (45) | 25 (38) | 11 (38) | 14 (38) |
| High | 11 (27.5) | 22 (34) | 11 (38) | 11 (30) |
| Therapy completion | 25 (62.5) | 43 (65) | 20 (69) | 23 (62) |
| Anticoagulation length (median mo) | 4 | 6.5 | 8 | 6 |
| (range) | 1-33 | 0.3-40 | 2-29 | 0.3-40 |
- Citation: Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, Patel H, Elquza E, McBride A. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol 2019; 11(10): 866-876
- URL: https://www.wjgnet.com/1948-5204/full/v11/i10/866.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i10.866